Mind Medicine - MNMD STOCK NEWS

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced inducement grants for three new non-executive employees. The grants consist of options to purchase 121,500 common shares with an effective date of April 21, 2025.

The options' exercise price will match the closing price of MindMed's common shares on April 18, 2025. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting in monthly increments over the following three years, contingent on continued employment. These grants were approved by MindMed's Compensation Committee on April 16, 2025, in compliance with NASDAQ Rule 5635(c)(4).

MindMed (NASDAQ: MNMD) has initiated its Phase 3 Emerge study by dosing the first patient with MM120 ODT, a proprietary form of LSD, for Major Depressive Disorder (MDD) treatment. The study will evaluate MM120 ODT 100 µg versus placebo, enrolling approximately 140 U.S. participants.

The 52-week Emerge study consists of two parts: a 12-week double-blind, placebo-controlled phase and a 40-week extension period. The primary endpoint will measure changes in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6. Topline data from the double-blind period is expected in H2 2026.

This marks MindMed's third Phase 3 study of MM120 ODT, alongside ongoing Voyage and Panorama studies in Generalized Anxiety Disorder (GAD). The development builds on positive Phase 2b results, which showed significant MADRS score improvements after a single MM120 100 µg dose compared to placebo.

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced inducement grants for four new non-executive employees. The grants consist of options to purchase 88,950 common shares with an effective date of March 24, 2025.

The options' exercise price will match the closing price of MindMed's common shares on March 21, 2025. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the subsequent three years, contingent on continued employment. These grants, approved by MindMed's Compensation Committee on March 19, 2025, were issued outside the company's equity incentive plans as employment inducements under NASDAQ Rule 5635(c)(4).

MindMed (NASDAQ: MNMD) has appointed Matt Wiley as Chief Commercial Officer (CCO) to oversee the company's commercial strategy as it prepares for the potential launch of MM120, an orally disintegrating tablet for generalized anxiety disorder (GAD) and major depressive disorder (MDD).

Wiley brings over 25 years of experience in sales, marketing, and strategic leadership across multiple specialty product launches. He previously served as CCO at BioXcel Therapeutics and VYNE Therapeutics, and as Vice President of Marketing at Jazz Pharmaceuticals where he led XYREM® to blockbuster status.

As part of his appointment, Wiley received inducement awards including:

• 350,000 common share options vesting over four years
• 125,000 performance stock units (PSUs) vesting on the third anniversary, with potential earnings of 0-200% based on performance metrics

MindMed (NASDAQ: MNMD) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company has $273.7 million in cash as of December 31, 2024, following successful equity financings totaling $250 million, extending operations into 2027.

Key developments include: First patients dosed in Phase 3 Voyage and Panorama studies of MM120 ODT for Generalized Anxiety Disorder (GAD), with topline data expected in 1H 2026 and 2H 2026 respectively. The company plans to initiate Emerge, the first Phase 3 study for Major Depressive Disorder (MDD), in 1H 2025.

Financial highlights:

• R&D expenses increased to $65.3 million in 2024 from $52.1 million in 2023
• G&A expenses decreased to $38.6 million in 2024 from $41.7 million in 2023
• Net cash used in operations was $79.1 million in 2024 versus $64.4 million in 2023

MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025. The company's management team will engage in a fireside chat and one-on-one meetings at the event, scheduled for March 11, 2025, at 3:40 PM ET in Miami Beach, FL.

Interested parties can access the presentation through a webcast, with audio recordings and replays remaining available on MindMed's Investor Relations website for up to 90 days after the event.

MindMed (MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced it will host a live webcast on March 6, 2025, at 8:00 a.m. ET. During the webcast, the company will present its fourth quarter and full-year 2024 financial results and provide business updates.

The webcast will be accessible through a registration link, with a separate link provided for analysts who wish to participate in the Q&A session. Participants are advised to join 15 minutes before the start time. A replay will be available through MindMed's Investor Relations website and will be archived for at least 30 days.

MindMed (NASDAQ: MNMD), a late-stage biopharmaceutical company focused on brain health disorders, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will engage in a fireside chat and one-on-one meetings during the virtual event, scheduled for February 12, 2025, at 9:20 AM ET.

Audio webcasts and replays of the presentations will be made available on MindMed's Investor Relations website, remaining accessible for up to 90 days after the event. This conference participation represents an opportunity for the company to showcase its developments in brain health treatments to the investment community.

MindMed (NASDAQ: MNMD) has initiated Panorama, its second Phase 3 study of MM120 ODT (lysergide D-tartrate) for Generalized Anxiety Disorder (GAD), with the first patient now dosed. The study will evaluate a proprietary, pharmaceutically optimized form of LSD against placebo, enrolling approximately 250 participants across US and Europe.

The 52-week trial consists of two parts: a 12-week double-blind, placebo-controlled period and a 40-week extension period for open-label treatment. Participants will be randomized in a 2:1:2 ratio to receive MM120 ODT 100 µg, 50 µg, or placebo. The primary endpoint will measure changes in Hamilton Anxiety Rating Scale (HAM-A) score at week 12.

The study builds on positive Phase 2b results presented at the American Psychiatric Association's Annual Meeting in May 2024. Topline data from the 12-week double-blind period is expected in the second half of 2026.